Available Clinical Trials at Pacific Cancer Care
Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.
For more information regarding clinical trial opportunities, please contact us at (831) 375-4105.
Advanced Unresectable or Metastatic Solid Malignancy
NCT #04632992
MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations Or Protein Expression Patterns Predictive or Response
Breast Cancer
NCT #04895358
Keynote-B49: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) in locally recurrent inoperable or Metastatic Breast Cancer
Head and Neck Squamous Cell Carcinoma
NCT #04338399
BURAN: Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hematologic Malignancies
NCT #03598608
MK4280-003: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab in Participants with Hematologic Malignancies
Hematologic Malignancies
NCT #03893682
APTOSE: Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin’s Lymphomas
Precision Medicine
NCT #04843332
Reducing Cancer Disparities Through Innovative Community-Academic Partnership to Advance Access and Delivery of Precision Medicine in Monterey County
Ovarian Cancer
NCT# 05116189
MK3475-B96: A Phase 3 Study of Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Prostate Cancer
NCT# 03706365
JPCM: A Phase 2/3 Study of Abiraterone Plus Prednisone With or Without Abemaciclib (LY2835219 in Participants with Prostate Cancer
